Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb
Gecertificeerd

Anti-IL17A (Cosentyx) (secukinumab biosimilar) mAb

Catalog #: 12-9156-100
Maat: 100 µg

Kwaliteit

ISO Gecertificeerd

Levering

24-48 uur

Prijs -1%
Login voor prijs
BTW niet inbegrepen
Gratis verzending vanaf €100
Technische Documentatie

Technische Specificaties

Description

Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-made through genetic engineering techniques and closely related to a protein that occurs naturally in the body. Secukinumab blocks an inflammatory protein called IL-17, thus improving joint pain and swelling from arthritis and rash from psoriasis. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

Product Name Alternative

CTLA-8, CTLA8, IL-17, IL-17A, IL17

Reactivity

Human

Target Antigen

IL17A

Clonality

• Monoclonal

Applications

FACS

Purification

Purified from cell culture supernatant by affinity chromatography

Storage Conditions

Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing) .Lyophilized proteins are shipped at ambient temperature.

Applications Notes

FACS 1:100

Isotype

IgG1

Beschrijving

Secukinumab (Cosentyx) is a biologic medication used to treat psoriatic arthritis, moderate to severe plaque psoriasis. Biologics are medicines that are human-m

Specificaties

ProductnaamAnti-IL17A (Cosentyx) (secukinumab biosimilar) mAb
Categorie
Beschikbare grootte100 µg
Catalogusnummer12-9156-100